Riluzole sublingual - Biohaven Pharmaceutical

Drug Profile

Riluzole sublingual - Biohaven Pharmaceutical

Alternative Names: BHV-0223

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company; Yale University
  • Class Benzothiazoles; Neuroprotectants; Small molecules; Thiazoles
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Spinocerebellar degeneration
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Social phobia
  • Phase I Generalised anxiety disorder; Mood disorders
  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 04 Jan 2017 Chemical structure information added
  • 01 Jan 2017 Phase-II/III clinical trials in Social phobia (Adjunctive treatment) in USA (Sublingual) (NCT03017508)
  • 09 Dec 2016 Preclinical trials in Amyotrophic lateral sclerosis in USA (Sublingual) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top